These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 33016814)

  • 21. Assessing the Cost-Utility of Universal Hepatitis B Vaccination Among Adults.
    Hall EW; Weng MK; Harris AM; Schillie S; Nelson NP; Ortega-Sanchez IR; Rosenthal E; Sullivan PS; Lopman B; Jones J; Bradley H; Rosenberg ES
    J Infect Dis; 2022 Sep; 226(6):1041-1051. PubMed ID: 35260904
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Cost-utility analysis on universal childhood hepatitis A vaccination in regions with different anti-HAV prevalence rates of China].
    Pan XJ; Feng YM; Zhuang GH
    Zhonghua Liu Xing Bing Xue Za Zhi; 2012 Aug; 33(8):862-6. PubMed ID: 22967346
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model.
    Gomez JA; Lepetic A; Demarteau N
    BMC Public Health; 2014 Nov; 14():1222. PubMed ID: 25424716
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness analysis of vaccination against COVID-19 in China.
    Zhou H; Ding N; Han X; Zhang H; Liu Z; Jia X; Yu J; Zhang W
    Front Public Health; 2023; 11():1037556. PubMed ID: 36960359
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The doses of 10 μg should replace the doses of 5 μg in newborn hepatitis B vaccination in China: A cost-effectiveness analysis.
    Yin J; Ji Z; Liang P; Wu Q; Cui F; Wang F; Liang X; Zhuang G
    Vaccine; 2015 Jul; 33(31):3731-8. PubMed ID: 26057138
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeted outreach hepatitis B vaccination program in high-risk adults: The fundamental challenge of the last mile.
    Mangen MJ; Stibbe H; Urbanus A; Siedenburg EC; Waldhober Q; de Wit GA; van Steenbergen JE;
    Vaccine; 2017 May; 35(24):3215-3221. PubMed ID: 28483198
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness analysis of hepatitis B vaccine booster in children born to HBsAg-positive mothers in rural China.
    Wang Y; Shi JF; Wang L; Yan Y; Yao H; Dai M; Chen T; Qu C
    Int J Infect Dis; 2019 Jan; 78():130-139. PubMed ID: 30466898
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of human papillomavirus vaccination for adolescent girls in Punjab state: Implications for India's universal immunization program.
    Prinja S; Bahuguna P; Faujdar DS; Jyani G; Srinivasan R; Ghoshal S; Suri V; Singh MP; Kumar R
    Cancer; 2017 Sep; 123(17):3253-3260. PubMed ID: 28472550
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Use the Markov-decision tree model to optimize vaccination strategies of hepatitis E among women aged 15 to 49].
    Chen ZM; Ji SB; Shi XL; Zhao YY; Zhang XF; Jin H
    Zhonghua Liu Xing Bing Xue Za Zhi; 2017 Feb; 38(2):267-271. PubMed ID: 28231679
    [No Abstract]   [Full Text] [Related]  

  • 30. Public Health Impact and Cost-Effectiveness of Hepatitis A Vaccination in the United States: A Disease Transmission Dynamic Modeling Approach.
    Dhankhar P; Nwankwo C; Pillsbury M; Lauschke A; Goveia MG; Acosta CJ; Elbasha EH
    Value Health; 2015 Jun; 18(4):358-67. PubMed ID: 26091589
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-Effectiveness of an Opioid Abuse-Prevention Program Using the Narcotics Information Management System in South Korea.
    Kim S; Kim E; Suh HS
    Value Health; 2021 Feb; 24(2):174-181. PubMed ID: 33518023
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hepatitis B immunization: cost calculation in a community-based study in India.
    Sahni M; Jindal K; Abraham N; Aruldas K; Puliyel JM
    Indian J Gastroenterol; 2004; 23(1):16-8. PubMed ID: 15106709
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Economic evaluation of varicella vaccination strategies in Jiangsu province, China: a decision-tree Markov model.
    Wang Q; Xiu S; Yang L; Huang J; Cui T; Shi N; Wang X; Shen Y; Chen E; Lu B; Jin H; Lin L
    Hum Vaccin Immunother; 2021 Nov; 17(11):4194-4202. PubMed ID: 34357833
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness analysis of introducing universal human papillomavirus vaccination of girls aged 11 years into the National Immunization Program in Brazil.
    Novaes HM; de Soárez PC; Silva GA; Ayres A; Itria A; Rama CH; Sartori AM; Clark AD; Resch S
    Vaccine; 2015 May; 33 Suppl 1():A135-42. PubMed ID: 25919154
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An economic evaluation of universal infant vaccination strategies against hepatitis B in Thailand: an analytic decision approach to cost-effectiveness.
    Vimolket T; Poovorawan Y
    Southeast Asian J Trop Med Public Health; 2005 May; 36(3):693-9. PubMed ID: 16124440
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hepatitis B immunization in a low-incidence province of Canada: comparing alternative strategies.
    Wiebe T; Fergusson P; Horne D; Shanahan M; Macdonald A; Heise L; Roos LL
    Med Decis Making; 1997; 17(4):472-82. PubMed ID: 9343806
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pertussis vaccination in pregnancy in Canada: a cost-utility analysis.
    Abu-Raya B; Coyle D; Bettinger JA; Vaudry W; Halperin SA; Sadarangani M;
    CMAJ Open; 2020; 8(4):E651-E658. PubMed ID: 33077536
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Regional variation in the cost effectiveness of childhood hepatitis A immunization.
    Jacobs RJ; Greenberg DP; Koff RS; Saab S; Meyerhoff AS
    Pediatr Infect Dis J; 2003 Oct; 22(10):904-14. PubMed ID: 14551492
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative outcomes and cost-utility following surgical treatment of focal lumbar spinal stenosis compared with osteoarthritis of the hip or knee: part 2--estimated lifetime incremental cost-utility ratios.
    Rampersaud YR; Tso P; Walker KR; Lewis SJ; Davey JR; Mahomed NN; Coyte PC
    Spine J; 2014 Feb; 14(2):244-54. PubMed ID: 24239803
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness analysis of infant universal routine pneumococcal vaccination in Malaysia and Hong Kong.
    Wu DB; Roberts C; Lee VW; Hong LW; Tan KK; Mak V; Lee KK
    Hum Vaccin Immunother; 2016; 12(2):403-16. PubMed ID: 26451658
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.